(NYSE: BDX) Becton Dickinson & Co's forecast annual revenue growth rate of 4.49% is not forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 8.51%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.83%.
Becton Dickinson & Co's revenue in 2025 is $21,386,000,000.On average, 7 Wall Street analysts forecast BDX's revenue for 2026 to be $6,529,181,416,788, with the lowest BDX revenue forecast at $6,465,742,445,702, and the highest BDX revenue forecast at $6,643,451,476,482. On average, 6 Wall Street analysts forecast BDX's revenue for 2027 to be $6,786,828,269,025, with the lowest BDX revenue forecast at $6,693,897,911,026, and the highest BDX revenue forecast at $6,924,633,023,571.
In 2028, BDX is forecast to generate $6,927,785,925,730 in revenue, with the lowest revenue forecast at $6,927,785,925,730 and the highest revenue forecast at $6,927,785,925,730.